1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Dr Reddy's Increases API Operational Efficiency With Customer Service Portal

 
• By Grace Montgomery

Dr Reddy’s has strengthened operational efficiency for its generics API customers by launching a customer service portal that enables users to “manage the whole business process in real time”.

Call Centre
Dr Reddy's' Xceed customer service portal allows users to track API info • Source: Shutterstock

Dr Reddy’s has launched an "advanced business-to-business customer service portal" to increase operational efficiency for its active pharmaceutical ingredient (API) customers. Stating that the ‘XCEED’ portal was “fully focused on meeting the growing demand for Dr Reddy’s portfolio of generic APIs”, the Indian firm maintained that XCEED “significantly increases the operational efficiency in doing business” with the company.

Designed based on customers’ insights and feedback, the “no-boundaries” platform “is a huge step forward in providing an advanced customer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

FDA Inspection Finds Leaks and Mold at Sun Pharma Halol Facility

 
• By Dean Rudge

Sun Pharma is facing renewed scrutiny after a scathing US Food and Drug Administration inspection at its Halol facility in Gujarat painted a grim picture of a facility operating in disregard of basic pharmaceutical safety standards.

Cipla CEO On Tariff Threat: ‘We Have One Of The Most Well Diversified Models’

 
• By Anju Ghangurde

Cipla's leadership fields shareholder queries on the specter of US tariffs and also outlines how the firm is nurturing the business for the future in areas like mRNA and point-of-care diagnostics, while building on its strength in the respiratory space.

Amphastar Unveils Plans To Quadruple US Manufacturing

 
• By Dave Wallace

Amphastar has announced plans to quadruple its domestic production capacity over the next three to five years. The move plays into a growing trend towards US manufacturing localization, against the backdrop of potential pharmaceutical tariffs being mooted by the Trump administration.

Kirsty Gives Biocon A First Interchangeable US Insulin Aspart Biosimilar

 
• By Dave Wallace

After years of waiting, Biocon Biologics has finally snagged US FDA approval for its insulin aspart biosimilar – along with a first designation of interchangeability. However, Sanofi’s Merilog version is already approved as a rival to Novo Nordisk’s Novolog.

More from Business